Kimia Biosciences Q1 Results Revenue Rs. 223,993 Million & Net Profit Rs. 143.70 Million

Kimia Biosciences Q1 Results: Kimia Biosciences reported its financial results for the first quarter ended on June 30, 2024. The company's revenue from operations was Rs. 223,993, which is lower compared to Rs. 303,017 reported for the year ended March 31, 2024, and Rs. 242,301 for the same quarter last year. The total income, which includes other income, was Rs. 2,240.26 million for the quarter, compared to Rs. 3,060.46 million for the year-end and Rs. 2,435.5 million for the same quarter last year.

The company's expenses for the quarter were Rs. 2,070.06 million, lower than Rs. 2,829.91 million for the year-end but higher than Rs. 2,797.69 million for the same quarter last year. Key expense components included Rs. 1,497.22 million for the cost of materials, a decrease in inventories by Rs. 274.57 million, and Rs. 34.283 million for employee benefits. Finance costs were Rs. 11,084 million, and other expenses totaled Rs. 303.96 million.

The profit before exceptional items and tax was Rs. 178.20 million, which improved from a loss of Rs. 362.16 million in the same quarter last year. The net profit for the quarter was Rs. 143.70 million, compared to a loss of Rs. 271.05 million in the same quarter last year. The earnings per share were Rs. 0.30, showing a significant improvement from Rs. (0.57) in the previous year.

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Kimia Biosciences Q1 Results

Here’s the Results table: 

Kimia Biosciences Stock Performance

Kimia Biosciences' stock information shows that its market capitalization is ₹246 crore, meaning the total value of all its shares combined is this amount. The current price of one share is ₹52.00. Over the past period, the highest price was ₹58.40, and the lowest was ₹33.20. The stock’s price-to-earnings (P/E) ratio is not provided, and its book value is very low at ₹0.07. 

Here’s the stock information in table format:

Quarterly Results 

Kimia Biosciences' financial performance over several quarters. It includes key figures like sales, expenses, operating profit, and net profit for each period. For December 2023, the company had sales of 26.14 crores and expenses of 27.19 crores, resulting in an operating loss of 1.05 crores. 

Here’s the full information in the table: 

(Figures in Rs. Crores)

About Kimia Biosciences

Kimia Biosciences is a company focused on advancing the pharmaceutical industry. Its journey began with a commitment to research and development (R&D), starting with a team of 120 people and a strong Intellectual Property Rights (IPR) team. In 2015, the company made a significant move by acquiring Laurel Organics, which was listed in 2016.

 By 2017, Kimia Biosciences had achieved important milestones, including obtaining WHO GMP accreditation in 2019 and DSIR R&D accreditation in 2017. The company also filed the Korean Drug Master File (KDMF) for two key products: Benfotiamine and Fimasartan Potassium Hydrochloride.

Kimia Biosciences started In 2017 and its export business in Pakistan and quickly expanded its reach, exporting to over 15 countries between 2018 and 2020, and successfully entering the US market in 2021. The company also upgraded its facilities with modern microbiology labs, a new water system, five clean rooms, and in-house micronization.